Biotech and Pharmaceuticals
FDA fast-tracks psychedelic drug research following Trump executive order
FILE PHOTO: Psilocybin or “magic mushrooms” are seen in an undated photo provided by the U.S. Drug Enforcement Agency (DEA) in Washington, U.S. May 7, 2019. DEA | Reuters The U.S. Food and Drug Administration on Friday announced a series of measures aimed at accelerating the development of psychedelic treatments for serious mental illness. That […]
Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]
Read More
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche reported falling sales in the first three months of the year, as the strength of the Swiss franc and generic competition for some of its older drugs weighed on the drugmaker. First-quarter sales came in at 14.7 billion Swiss francs ($18.7 billion), down 5% year-on-year — but up 6% on a constant currency basis. […]
Read More
RFK Jr. says he would support a potential ban on junk food TV ads
U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. gestures as he speaks during an event at the Roosevelt Room of the White House in Washington, D.C., U.S., Dec. 19, 2025. Evelyn Hockstein | Reuters Health and Human Services Secretary Robert F. Kennedy Jr. on Wednesday said he would support a potential ban […]
Read More
UnitedHealth tops quarterly estimates, hikes profit outlook as insurer manages high medical costs
UnitedHealthcare sign is displayed at its office building in Minnetonka, Minnesota, U.S., Dec. 11, 2025. Tim Evans | Reuters UnitedHealth Group on Tuesday posted first-quarter earnings that topped estimates and hiked its 2026 profit outlook, as the company better manages high medical costs and streamlines its operations. The nation’s largest private insurer said it expects […]
Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]
Read More
Trump nominates Erica Schwartz as CDC director amid turmoil around leadership, vaccine policy
Rear Admiral Erica G. Schwartz. U.S. Department of Health and Human Services President Donald Trump on Thursday nominated Erica Schwartz to serve as director of the Centers for Disease Control and Prevention, concluding a monthslong effort to choose a permanent leader of the embattled health agency. Schwartz will have to be confirmed by the Senate, […]
Read More
Cramer’s lightning round: Nokia still has room to run
Stock Chart IconStock chart icon Gilead Sciences’ year-to-date stock performance. Gilead Sciences: “I like what Daniel O’Day is doing…I think he’s a smart guy, and the company’s good. I’d hold on to it. They’ve got some good franchises.” Stock Chart IconStock chart icon AST SpaceMobile’s year-to-date stock performance. AST Space Mobile: “I like it very […]
Read More
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk is partnering with OpenAI to “bring new and better treatment options to patients faster,” the Danish drugmaker said Tuesday. The partnership will enable Novo to better […]
Read More
Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial
Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all […]
Read More